Posted by Michael Wonder on 25 Nov 2020
NICE publishes final guidance on Nubeqa
25 November 2020 - NICE has completed its assessment of darolutamide for use in combination with androgen deprivation therapy for the treatment of men with hormone-relapsed non-metastatic prostate cancer.
Darolutamide with androgen deprivation therapy is recommended, within its marketing authorisation, as an option for treating hormone-relapsed prostate cancer in adults at high risk of developing metastatic disease. It is recommended only if Bayer provides darolutamide according to the commercial arrangement.
